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ABSTRACT 
 
 
Background 
The Epidemiologic Study of Cystic Fibrosis using 1995-1996 and 2003-2005 data found that CF 
centres with lowest FEV1 tended to use fewer intravenous antibiotics. We repeated the analyses 
using 2013-2014 UK CF registry data to determine if this was still the case. 
 
 
Methods 
Analysing data for 2013 and 2014 separately, 28 adult CF centres were ranked according to 
median % age-adjusted FEV1. The toSFHQWUHVZHUHSODFHG LQ WKH µXSSHUTXDUWHU¶ (best FEV1), 
WKH ERWWRP  FHQWUHV LQ µORZHU TXDUWHU¶ (lowest FEV1), and the UHVW LQ µPLGGOH KDOI¶. IV use was 
stratified according to %FEV1, then compared between the three groups.  
 
 
Results 
&HQWUHVLQWKHµXSSHUTXDUWHU¶and µPLGGOHKDOI¶ used significantly more IV antibiotics compared to 
FHQWUHVLQWKHµORZHUTXDUWHU¶ (van Elteren test p-value <0.001). Regression analyses showed that 
SHRSOHZLWK&)DWWHQGLQJFHQWUHVLQWKHµXSSHUTXDUWHU¶RU µPLGGOHKDOI¶DUH-50% more likely to 
receive at least one IV course per year compared to people DWWHQGLQJFHQWUHVLQWKHµORZHUTXDUWHU¶ 
 
 
Conclusions 
CF centres with lowest FEV1 are still distinguished by lower use of intravenous antibiotics. 
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1. INTRODUCTION 
CF is an archetypal long-term condition in which treatment involves both reactive, disruptive and 
expensive hospital based rescue using intravenous (IV) antibiotics and community based 
prevention using inhaled therapies. IV antibiotics to treat pulmonary exacerbations are needed as 
rescue when preventive therapy fails to achieve stability.  
Intensive IV use, in the form of scheduled IV courses not primarily driven by symptoms, was first 
noted to be beneficial in a Danish observational study [1]. 5-year survival improved from 54% in 
1971-75 to 82% in 1976-80 following routine IV administration every 3-4 months for people with 
chronic Pseudomonas [1]. Intensive IV use gained further acceptance after the Epidemiologic 
Study of Cystic Fibrosis (ESCF) using 1995-1996 data showed that North American centres with 
higher FEV1 also have higher IV use [2]. Indeed, regular IV use became such an ingrained practice 
WKDW D UDQGRPLVHG FRQWURO WULDO LQ ODWH ¶V  DLPLQJ WR FRPSDUH URXWLQH -monthly) vs elective 
(only when symptomatic) IV found similar IV usage in both arms [3].  
Preventive LQKDOHG WKHUDSLHVDQWLELRWLFVDQGPXFRO\WLFVEHFDPHDYDLODEOH IURP¶VRQZDUGV
and prescriptions of these increased from 1995-2005 [4,5]. Regular use of preventive therapy 
might be expected to reduce the need for IV antibiotics, given that randomised clinical trials of 
inhaled therapies typically demonstrates a reduction in exacerbation [6,7]. However, analysis of the 
2003-2005 ESCF data found that centres with higher FEV1 continued to use more IV [8]. 
Intensive IV use is not without its drawbacks. As CF survival continues to improve [9,10], increased 
cumulative exposure to high doses of IV antibiotics could increase the frequency and severity of 
systemic side-effects, particularly renal failure [11,12]. Since 2005, newer classes of inhaled 
therapies have been introduced and prescriptions of these have also increased [13]. In this 
decade, the plethora of efficacious inhaled therapies [6,7] might be expected to allow CF centres to 
move away from dependence on IV antibiotics. This might mean that centres using less IV may no 
longer have the lowest FEV1. However, such a desirable change cannot be taken for granted 
because the mean composite medication possession ratio (MPR) data from a US study of 3287 
people with CF suggests <50% of preventive therapies were collected [14]. UK data suggest that 
median objectively measured adherence to inhaled therapies among adults is only 36% [15]. 
We therefore repeated the ESCF analysis using the 2013-2014 UK CF registry data to determine 
whether low IV use continues to be associated with centres with lower FEV1. We hypothesised that 
UK specialist adult CF centres with lower FEV1 are no longer distinguished by lower IV use 
because efficacious inhaled therapies are increasingly available. 
 
 
2. METHODS 
This cross-sectional analysis using the 2013-2014 UK CF registry data LQYROYHGSHRSOHDJHG
years with CF receiving care at all 28 UK specialist adult centres. People with lung transplantation 
or on ivacaftor were excluded since both treatments have transformative effects on FEV1 [16,17], 
such that their FEV1 no longer represent that of a typical adult with CF. 
 
2.1. Data 
Data obtained include demographics (age, gender, CF centre identifier), body mass index (BMI, in 
kg/m2), annual review FEV1 (in % predicted, calculated with Knudson equation) [18], annual IV 
antibiotic use (number of IV courses and total IV days per year) and prescription of preventive 
therapies (inhaled antibiotics, inhaled mucolytics and long-term oral macrolide). 
Data were collected during annual reviews from January 2013 to December 2014. Data for best 
annual FEV1, P. aeruginosa status and pancreatic status were also obtained for analyses detailed 
in Appendices B, C, E and F. 
 
2.2. Statistical methods 
Analyses were performed using SPSS v22 (IBM Corp) and R v3.3.0 (www.r-project.org). Data for 
2013 and 2014 were analysed separately. For each year, centres were ranked according to their 
median % age-adjusted FEV1WKHQGLYLGHGLQWRWKUHHJURXSVµXSSHUTXDUWHU¶ µPLGGOHKDOI¶ µORZHU
TXDUWHU¶,9XVHZDVWKHQVWUDWLILHGDFFRUGLQJWR)(91 for between-group comparison. 
CF specific age-adjustment for %FEV1 were performed using a generalised linear model approach 
to create an adjusted FEV1 taking account of FEV1 decline in CF populations [19]. For both 2013 
and 2014, the cohort was divided into 10 age groups with similar numbers of study subjects in 
each decile. 7KHµSUHGLFWHG¶)(91 for each age decile was calculated using a linear model (the 
resultant actual age adjustment was non-linear; see Appendix A). The % age-adjusted FEV1 is the 
actual %FEV1 divided by the predicted %FEV1 for people of this age with CF. Therefore, % age-
adjusted FEV1 >100% represents better than expected %FEV1 IRUDSHUVRQ¶VDJHZKHUHDVDJH-
adjusted FEV1 <100% represents worse than expected %FEV1 IRUDSHUVRQ¶VDJH7KHPHGLDQ
age-adjusted FEV1 for each centre was calculated to rank the centres from highest to lowest. The 
FHQWUHVZHUH WKHQGLYLGHG LQWRJURXSV7KH µXSSHUTXDUWHU¶FRQVLVWHGRI WKHFHQWUHVZLWK WKH
highest median % age-adjusted FEV1WKHµORZHUTXDUWHU¶FRQVLVWHGRIWKHFHQWUHVZLWKWKHORZHVW
median % age-adjusted FEV1 ZKLOVW WKH µPLGGOH KDOI¶ FRQVLVWHG RI WKH UHPDLQLQJ FHQWUHV LQ WKH
middle (n=13 for 2013, n=14 for 2014). The discrepancy between the number of centres in 2013 
and 2014 was due to one of the centres not providing any annual review data in 2013. Descriptive 
statistics of baseline characteristics were obtained for each group. The consistency of centre 
rankings from 2013-ZDVDVVHVVHGZLWK6SHDUPDQ¶VUKR 
For comparison of the annual IV use between the three groups, adults in each group were pooled 
and stratified according to %FEV1 (<40%, 40-WRDOORZFRPSDULVRQDPRQJFRKRUWVRI
adults with similar lung health and to control for case-mix confounding factors. These 
internationally used %FEV1 categories have been shown to be applicable to the UK CF registry 
data [20]. StUDWLILHG:LOFR[RQUDQNVXPWHVWZDVXVHGWRFRPSDUH,9XVHEHWZHHQµXSSHUTXDUWHU¶
YV µORZHU TXDUWHU¶ µXSSHU TXDUWHU¶ YV µPLGGOH KDOI¶ DQG µPLGGOH KDOI¶ YV µORZHU TXDUWHU¶ ZLWK
Bonferroni correction applied for multiple comparisons. Percentage of people prescribed at least 
one IV course per year were similarly compared, using the Cochran±Mantel±Haenszel test. Data 
on the prescription of preventive therapies, including inhaled antibiotics, inhaled mucolytics and 
long-term macrolide were also analysed in a similar method to IV use, to determine if there are 
other differences in the process of care that could influence FEV1. Cochran±Mantel±Haenszel test 
was used to compare these prescription data, which were available as binary variables (prescribed 
vs not prescribed). P-value <0.05 after Bonferroni correction was considered statistically 
significant. 
The methods described were similar to the ESCF methods [2], with minor differences. The ESCF 
analysis involved both paediatric and adult centres. We restricted the analysis to adult centres 
because we wanted to compare care in different centres, and the shared care arrangements in 
paediatrics made centre comparisons problematic [21]7KH(6&)DQDO\VHGHYHU\RQHDJHG
years as a single cohort without %FEV1 adjustment, whereas we adjusted %FEV1 for age in this 
analysis due to significant between-centre age differences in the UK [22]. ESCF used four FEV1 
categories for stratification (FEV1 ZDVLQFOXGHGZKHUHDVZHXVHGWKUHHFDWHJRULHVVLQFH
children who tend to have FEV1  ZHUH H[FOXGHG IURP WKLV DQDO\VLV (6&) DJJUHJDWHG
results over a 2-year period whereas we analysed the data year-by-year to determine the 
consistency of any oEVHUYHGGLIIHUHQFHV(6&)FRPSDUHGµXSSHU¶YV µORZHU¶TXDUWHUZKHUHDVZH
LQFOXGHGWKHµPLGGOHKDOI¶WRXQGHUVWDQGWKHSDWWHUQRI,9XVHDFURVVDOOFHQWUHV 
7KH QXPEHU RI DGXOWV LQ WKH µXSSHU¶ DQG µORZHU¶ TXDUWHUV RI WKLV DQDO\VLV LV ODUJHU WKDQ WKH DGXOW 
population in the ESCF study, which should allow for adequate power to detect differences in IV 
use across the three groups of centres. 
 
2.3. Further explanation of the statistical method 
Since this analysis set out to allow comparison of the 2013-2014 epoch with the original 1995-1996 
ESCF epoch where inhaled therapies were less widely used, our reported analysis in the main 
paper mirrors the ESCF methods [2]. An alternative method to control for confounding is 
regression modelling. As a sensitivity analysis, we have performed regression analysis for IV days 
and number of IV courses; adjusting for gender, age, pancreatic status, %FEV1 and P. aeruginosa 
status using a similar Generalised Linear Model (GLM) approach as described in Appendix A. This 
involved calculating the predicted IV days and number of IV courses for each study subject by 
fitting gender, age, pancreatic status, %FEV1 and P. aeruginosa status as categorical variables in 
a linear model. The case-mix adjusted IV days and IV courses for each study subject were then 
GHWHUPLQHGDQGFRPSDUHGEHWZHHQDOOWKUHHJURXSVRIVSHFLDOLVWDGXOW&)FHQWUHVµXSSHUTXDUWHU¶
µPLGGOHKDOI¶ µORZHUTXDUWHU¶:HDOVRXVHGDELQDU\ ORJLVWLFPRGHO WRFRPSDUH WKHSURSRUWLRQRI
people prescribed at least one course of IV antibiotics per year among all three groups of specialist 
adult CF centres, adjusting for the same set of categorical variables. Further explanation of these 
regression analyses and results are presented in Appendix B.  
We did not use a multi-level model to compare IV use of each CF centre because this approach is 
limited by the number of adults in smaller centres and potential systematic bias in annual review 
FEV1 data (further explanation in Appendix C). 
 
 
3. RESULTS 
4269 adults were included for 2013, and 4644 for 2014. Appendix D summarises the numbers of 
adults excluded and missing data. Centre ranking was consistent from 2013-2014, with 
6SHDUPDQ¶VUKRRI 
Table 1 summarises the characteristics of study subjects. Since centres were ranked according to 
% age-adjusted FEV1, the substantial between group differences in % age-adjusted FEV1 are as 
H[SHFWHG6RPHRIWKHFHQWUHV LQWKH µORZHUTXDUWHU¶KDYHDGXOWVWKDWZHUHVOLJKWO\ROGHUEXW WKLV
was likely due to those CF centres being established earlier rather than actual differences in 
survival. The %FEV1 differences between the three groups of centres were also disproportionate to 
DJHGLIIHUHQFHV$VVKRZQLQ7DEOHFHQWUHVLQWKHµXSSHUTXDUWHU¶KDYHVXSHULRU)(91 age-for-
age, indicating these centres have the best outcomes. In particular, FEV1 at the age of 20 years 
has been suggested as a good discriminator of outcomes [23] and there were clear stepwise 
increases in %FEV1 IURPµORZHUTXDUWHU¶WRµPLGGOHKDOI¶WRµXSSHUTXDUWHU¶LQWKDWDJHJURXS)XUWKHU
evidence regarding the robustness of the ranking process in identifying centres with better 
outcomes is provided in Appendix E.  
Tables 3-5 summarise the IV use for the three groups of CF centres. When comparing among 
DGXOWVZLWK WKHVDPH OXQJGLVHDVHVHYHULW\ FHQWUHV LQ WKH µXSSHUTXDUWHU¶DQG µPLGGOHKDOI¶XVHG
VLJQLILFDQWO\ PRUH ,9 DQWLELRWLFV FRPSDUHG WR FHQWUHV LQ WKH µORZHU TXDUWHU¶ IV use was not 
VWDWLVWLFDOO\GLIIHUHQWEHWZHHQFHQWUHV LQ WKH µXSSHUTXDUWHU¶DQG µPLGGOHKDOI¶7KHVH UHVXOWVZHUH
consistent for both 2013 and 2014. These results were not explained by differences in case-mix 
between the three groups of CF centres (detailed analysis of case-mix factors in Appendix F), and 
similar results were obtained using regression modelling (see Appendix B). 
Differences in the prescription of preventive therapies between the three groups of CF centres are 
summarised in Table 6. There was no clear signal in the prescription rates among the three groups 
and the differences were inconsistent from 2013-2014. It is unlikely these differences could explain 
the FEV1 differences between the three groups since the direction of differences is somewhat 
SDUDGR[LFDO ZLWK ORZHVW SUHVFULSWLRQV DPRQJ FHQWUHV LQ WKH µPLGGOH KDOI¶ +LJKHU SUHVFULSWLRQ RI
preventive therapies should not improve FEV1 RIWKHµXSSHUTXDUWHU¶FRPSDUHGWRWKHµPLGGOHKDOI¶
in 2013) whilst at the same time reduce FEV1 of the µORZHUTXDUWHU¶FRPSDUHGWRWKHµPLGGOHKDOI¶LQ
2014). Further analyses of preventive therapies data are presented in Appendix G. 
 
 
4. DISCUSSION 
This study found that UK adult CF centres with lowest FEV1 are distinguished from centres with 
better FEV1 by a lower use of IV antibiotics, rather than by prescription of preventive therapies. The 
ranking process used was robust in identifying the group of centres with better outcomes. 
Differences in case-mix did not explain the differences in IV use between centres. The 2013 results 
were consistent with 2014 results, suggesting that they are unlikely to be merely due to chance.  
There are some differences between the results of this study and the ESCF results. Analysis of the 
ESCF 1995-1996 dataset showed similar IV days across all FEV1 groups [2]. In the present study, 
those with FEV1 <40% required much more IV while those with FEV1 ZHUHRQYHU\OLWWOH,9
which would be consistent with preventive therapies being particularly effective at preventing 
exacerbations among those with higher FEV1. Another ESCF analysis found that incidence of IV 
use has decreased from 1995 to 2005, but the decrease was partially offset by lower threshold 
among clinicians with respect to pulmonary symptoms and signs in initiating IV antibiotics [24]. In 
WKH SUHVHQW VWXG\ ,9 XVH UHPDLQV KLJK GXULQJ WKH ¶V HVSHFLDOO\ DPRQJ SHRSOH ZLWK ORZHU
FEV1. Survival among people with FEV1 <30% has improved significantly over time [25], and it is 
not surprising this group would be particularly reliant on IV antibiotics. Analysis of the ESCF 1995-
1996 dataset also found most pronounced differences in IV days but similar number of IV courses 
among adults. In this study, there were significant differences in both the number of IV courses and 
IV GD\VEHWZHHQ&)FHQWUHVLQWKHµORZHUTXDUWHU¶DQGRWKHU&)FHQWUHV 
7KHUHVXOWVRIWKLVVWXG\HFKRWKHRYHUDOO(6&)UHVXOWVIURPWKH¶VDQG¶VDPRQJ1RUWK
American centres. This is somewhat surprising, because the increasing availability and prescription 
of efficacious preventive therapies, including dry powder inhalers, have the potential to reduce the 
dependency on IV antibiotics. Indeed, nearly 90% of all adults in this study were prescribed at least 
one form of preventive therapy. 
The limitations of a retrospective observational registry-based analysis have been previously 
discussed [26], but it is crucial to consider whether limitations of the UK CF registry dataset present 
a challenge to the validity of our findings. The UK CF registry do not routinely collect encounter-
based data, hence potentially important information such as number of clinic visits are not 
available. In the 1995-1996 ESCF analyses, centres in upper quarter achieved more frequent clinic 
visits [2]. Data on preventive therapies are available within the UK CF registry, but are not 
accompanied by any adherence data. Previous studies have shown little relationship between 
preventive medications that are prescribed and preventive medications that are collected, with 
MPR of around 50% for preventive inhaled therapies [14]. Even when a prescription is collected, 
the amount of treatment taken can be highly variable [27]. Date- and time-stamped objective 
adherence measurement in adult suggests that median adherence is less than 36%, whilst self-
UHSRUWHGDGKHUHQFHLVDQGFOLQLFLDQV¶HVWLPDWHGDGKHUHQFHLVSRRUO\FDOLEUDWHG [15]. The data 
for IV antibiotics is very different is that it typically reflects treatment that was actually used. Hence 
the UK registry data would not reliably reflect how much of the prescribed preventive therapy is 
actually used. On the other hand, if the registry data suggest a preventive therapy is not 
prescribed, it is likely the treatment has not been used. We could be relatively confident that adults 
not prescribed any preventive therapies were not using any of those therapies, hence they were 
different from those who were prescribed at least one type of preventive therapies. Comparing 
these two groups allows some sort of interpretation using the registry data for preventive therapy. 
The strong and consistent relationship that centres with lower FEV1 have lower IV use contrasts 
with the inconsistent relationship with the metrics recording what preventive inhaled therapies were 
prescribed.  
In using the ESCF methodology of aggregating centres into larger groups [2], we dealt with sample 
size issues and potential bias in annual review FEV1 that makes differentiating quality of care 
between individual centres difficult. This allows us to confidently identify a group of centres with 
lower FEV1 that also differed in a process of care measure. Age-for-age, there were clear stepwise 
differences in %FEV1 across the three different groups of centres that were not present during the 
transition age of 16 years (see Table 2 and Appendix E). These differences strongly suggest a 
JHQXLQHJUDGLHQWRIKHDOWKRXWFRPHVIURPµXSSHUTXDUWHU¶WRµORZHUTXDUWHU¶ZKLFKZDVQRWGXHWR
data or case-mix issues. Therefore, differences in the structure or processes of care, rather than 
case-mix, were likely to be responsible for the FEV1 differences observed. 
IV antibiotics are often taken as a surrogate for the frequency and severity of exacerbations. 
However, the 2003-2005 ESCF analyses show that centres using more IV did not have more 
exacerbations, but appeared to pay more attention to exacerbations and use more IV for the 
exacerbations that were paid attention to [8]. Similarly, our findings do not necessarily imply that 
centres with better FEV1 were more prone to exacerbations, but simply that more exacerbations 
were treated. Data suggest that higher numbers of exacerbations are found when more attention is 
paid, e.g. with home-monitoring [28]. Thus, it is likely that many exacerbations are under-
recognised and under-treated among people with CF. The 2003-2005 ESCF analyses also show 
that only around 50% of all exacerbations characterised by three / four Rabin criteria were actually 
treated with some form of additional antibiotics [8]. Those analyses, which stratified the distribution 
of IV use by indication, show that centres with highest FEV1 treated more exacerbations and 
treated those exacerbations more aggressively (with IV rather than oral antibiotics) [8]. This could 
indicate that ESCF centres with the highest FEV1 were able to monitor patients more attentively 
and intervene more often. The same metric of paying attention may well apply in the UK, with 
centres with better FEV1 detecting and treating more exacerbations. 
A recent ESCF analysis showed that treatment of exacerbations with antibiotics increases the 
likelihood of FEV1 recovery following an acute decline [29]. Centres with low IV use may be under-
recognising and under-treating exacerbations, leading to lower FEV1. Given that high quality care 
is often associated with structures that allow teams to pay attention to the metrics that matter [5], 
these results may reflect care structures that are not adapted to pay sufficient attention in detecting 
exacerbations and emphasising prevention. 
The continued dependence on IV use to achieve better FEV1, in an era in which efficacious 
preventive therapies are increasing available and prescribed, should prompt the CF community to 
reflect on strategies for more effective utilisation of preventive therapies. Preventive inhaled 
therapies are specifically marketed around their ability to preserve lung health and to reduce the 
risk of exacerbations. In controlled clinical trials, with adherence rates of 80-100% [30], their 
efficacy is beyond doubt with 3-10% FEV1 improvement and 20-50% risk reduction for 
exacerbations [6,7]. A likely reason for the failure of efficacious inhaled therapies to fully translate 
into clinical effectiveness is the real world adherence rates of only 35-50% [14,15]. There are on-
going efforts to develop even more efficacious preventive therapies, but effective behaviour 
change interventions to support medication adherence is probably just as important for effective 
utilisation of preventive therapies. 
 
 
5. CONCLUSIONS 
In the 30 years since the benefit of intensive IV antibiotic use among people with CF was 
demonstrated, CF care continues to improve and therapeutic options, especially for preventive 
FDUHFRQWLQXHWR LQFUHDVH<HW WKHXVHRI ,9DQWLELRWLFWUHDWPHQW WKDW LVGLVUXSWLYH WRSHRSOH¶V OLIH
and associated with significant complications still distinguishes the adult centres in the UK with the 
lowest FEV1 from centres with better FEV1.  
Intriguingly, centres with the best FEV1 used similar amount of IV antibiotics as centres with 
moderate FEV1 but seemed to have derived more benefit from their IV use. Analysis of the ESCF 
1995-1996 dataset found that the centres with the highest FEV1 appeared to pay more attention by 
reviewing people with CF more frequently and sending more respiratory samples [2]. It may be that 
the very best UK centres have developed relationships and structures that improve care by paying 
more attention to successful delivery of all care modalities, but this requires further investigation. 
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Table 1: Characteristics of adults with CF for the 3 groups of specialist CF centres ('upper quarter', 'middle half', 'lower quarter') for 2013-2014 
 
Centre ranking 
2013 2014 
Upper quarter Middle half Lower quarter Upper quarter Middle half Lower quarter 
 
Number of centres 
 
7 
 
13 
 
7 
 
7 
 
14 
 
7 
 
Number of adults with CF 
 
1036 
 
1952 
 
1281 
 
944 
 
2255 
 
1445 
 
Age, mean (SD) 
 
29.8 (10.9) 
 
29.7 (10.2) 
 
31.0 (10.5) 
 
29.9 (10.8) 
 
30.1 (10.6) 
 
31.6 (10.6) 
 
Female, (%) 
 
467 (45.1) 
 
903 (46.3) 
 
566 (44.2) 
 
436 (46.2) 
 
1021 (45.3) 
 
639 (44.2) 
 
BMI, mean (SD) 
 
22.9 (3.9) 
 
22.6 (4.0) 
 
22.3 (3.7) 
 
22.8 (4.1) 
 
22.7 (4.0) 
 
22.3 (3.6) 
 
Unadjusted % FEV1, mean (SD) 
 
        Number of adults with FEV1  
        and IV days data § 
 
        FEV1 < 40%, (%) 
        FEV1 40% to 69.9%, (%) 
        FEV1 , (%)  
 
68.1 (23.9) 
 
981 
 
135 (13.8) 
372 (37.9) 
474 (48.3)  
 
65.2 (24.8) 
 
1867 
 
343 (18.4) 
717 (38.4) 
807 (43.2) 
 
62.1 (25.3) 
 
1244 
 
294 (23.6) 
464 (37.3) 
486 (39.1) 
 
69.4 (24.4) 
 
871 
 
125 (14.4) 
299 (34.3) 
447 (51.3) 
 
66.8 (24.9) 
 
2167 
 
359 (16.6) 
819 (37.8) 
989 (45.6) 
 
62.1 (25.0) 
 
1411 
 
331 (23.5) 
539 (38.2) 
541 (38.3) 
 
% Age-adjusted FEV1, mean (SD) 
 
104.5 (36.6) 
 
100.3 (38.0) 
 
96.0 (38.7) 
 
105.4 (37.1) 
 
101.1 (37.3) 
 
95.0 (37.9) 
 
§
 Missing data as detailed in Appendix B. 
  
Table 2: % predicted FEV1 at annual review for the three groups of specialist CF centres for 2013-2014, stratified according to age: 
% predicted FEV1 
at annual review, 
median (IQR) 
2013 2014 
Upper quarter 
(n = 981) 
Middle half 
(n = 1867) 
Lower quarter 
(n = 1244) 
Upper quarter 
(n = 871) 
Middle half 
(n = 2167) 
Lower quarter 
(n = 1411) 
Age 16 ± 19 years 
Age 20 ± 21 years 
Age 22 ± 23 years 
Age 24 ± 25 years 
Age 26 ± 27 years 
Age 28 ± 30 years 
Age 31 ± 33 years 
Age 34 ± 37 years 
Age 38 ± 44 years 
Age \HDUV 
82.1 (62.9 ± 93.8) 
75.4 (50.5 ± 91.4) 
69.2 (53.0 ± 85.0) 
70.4 (52.8 ± 85.7) 
62.5 (45.4 ± 81.5) 
68.3 (46.2 ± 85.3) 
65.3 (46.3 ± 78.8) 
64.9 (47.1 ± 84.5) 
66.3 (45.8 ± 85.4) 
66.5 (40.9 ± 85.8) 
75.9 (55.0 ± 91.5) 
70.5 (48.0 ± 88.4) 
66.7 (48.2 ± 81.7) 
64.0 (45.9 ± 84.5) 
63.2 (42.1 ± 79.6) 
63.8 (46.7 ± 83.0) 
58.0 (40.2 ± 81.0) 
60.3 (46.4 ± 76.2) 
63.6 (41.5 ± 80.3) 
59.9 (45.0 ± 82.5) 
72.6 (52.1 ± 86.1) 
67.3 (46.8 ± 86.7) 
69.4 (50.8 ± 86.6) 
56.4 (35.1 ± 83.0) 
61.8 (43.5 ± 85.9) 
58.9 (40.0 ± 80.1) 
54.2 (36.4 ± 74.8) 
55.1 (39.1 ± 76.8) 
59.7 (42.2 ± 78.4) 
52.4 (35.9 ± 76.6) 
80.4 (61.9 ± 92.3) 
80.0 (59.5 ± 93.1) 
75.1 (54.1 ± 88.9) 
71.9 (58.1 ± 84.6) 
60.3 (42.5 ± 81.3) 
69.1 (54.2 ± 86.0) 
62.5 (41.1 ± 84.1) 
60.7 (44.0 ± 81.6) 
74.4 (50.6 ± 90.0) 
65.6 (48.8 ± 91.6) 
80.0 (58.7 ± 94.3) 
76.0 (57.5 ± 91.7) 
67.0 (47.5 ± 85.6) 
66.0 (46.9 ± 85.0) 
59.0 (43.4 ± 80.6) 
64.7 (45.6 ± 80.1) 
62.5 (42.8 ± 82.4) 
62.2 (47.6 ± 80.7) 
61.6 (44.5 ± 81.4) 
58.7 (41.9 ± 81.2) 
71.6 (56.1 ± 87.5) 
71.0 (43.0 ± 87.1) 
65.9 (48.6 ± 84.0) 
67.8 (47.8 ± 79.0) 
63.5 (46.4 ± 82.0) 
58.4 (39.3 ± 81.5) 
55.7 (35.7 ± 74.9) 
56.3 (39.1 ± 78.0) 
56.8 (40.6 ± 75.9) 
50.2 (35.0 ± 72.9) 
 
For 2013 
P-value for upper quarter vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for middle half vs lower quarter = 0.002 (after Bonferroni correction, p-value = 0.007) 
P-value for upper quarter vs middle half = 0.003 (after Bonferroni correction, p-value = 0.010) 
 
For 2014 
P-value for upper quarter vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for middle half vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for upper quarter vs middle half = 0.002 (after Bonferroni correction, p-value = 0.007) 
 
 
*P-values were calculated for % predicted FEV1 stratified according to age using the stratified Wilcoxon rank sum test (van Elteren test). This test is an extension of the Wilcoxon rank 
sum test that uses within-stratum ranks to compare two groups that are stratified. For references, see: 
van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst1960;37(3):351-361. 
Kawaguchi A, Koch GG. Sanon: an R package for stratified analysis with nonparametric covariable adjustment. J Stat Softw. 2015;67(9):1±37. 
Table 3: Annual number of IV courses for the three groups of specialist CF centres ('upper quarter', 
'middle half', 'lower quarter') for 2013 and 2014 
 
 2013 2014 
Upper 
quarter 
(n = 981) 
Middle 
half 
(n = 1867) 
Lower 
quarter 
(n = 1244) 
Upper 
quarter 
(n = 871) 
Middle 
half 
(n = 2167) 
Lower 
quarter 
(n = 1411) 
 
Annual number IV 
antibiotic courses, 
median (IQR) 
 
 
 
1 (0 ± 2) 
 
 
 
1 (0 ± 3) 
 
 
 
1 (0 ± 2) 
 
 
 
1 (0 ± 2) 
 
 
 
1 (0 ± 3) 
 
 
 
1 (0 ± 2) 
 
Annual number IV 
antibiotic courses, 
stratified according 
to FEV1, 
median (IQR) 
 
FEV1 < 40% 
FEV1 40% to 69.9% 
FEV1  
 
 
 
 
 
 
3 (2 ± 5) 
1 (0 ± 3) 
0 (0 ± 1) 
 
 
 
 
 
 
3 (1 ± 5) 
1 (0 ± 3) 
0 (0 ± 1) 
 
 
 
 
 
 
2 (1 ± 5) 
1 (0 ± 2) 
0 (0 ± 1) 
 
 
 
 
 
 
3 (1 ± 5) 
1 (0 ± 3) 
0 (0 ± 1) 
 
 
 
 
 
 
3 (1 ± 5) 
1 (0 ± 3) 
0 (0 ± 1) 
 
 
 
 
 
 
2 (1 ± 4) 
1 (0 ± 2) 
0 (0 ± 1) 
 
For 2013 
P-value for upper quarter vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for middle half vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for upper quarter vs middle half = 0.518 (after Bonferroni correction, p-value = 1) 
 
 
For 2014 
P-value for upper quarter vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for middle half vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for upper quarter vs middle half = 0.247 (after Bonferroni correction, p-value = 0.740) 
 
 
*P-values were calculated for annual number of IV antibiotics courses stratified according to FEV1 
using the stratified Wilcoxon rank sum test (van Elteren test). This test is an extension of the 
Wilcoxon rank sum test that uses within-stratum ranks to compare two groups that are stratified. 
For references, see: 
van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat 
Inst1960;37(3):351-361. 
Kawaguchi A, Koch GG. Sanon: an R package for stratified analysis with nonparametric covariable 
adjustment. J Stat Softw. 2015;67(9):1±37.  
Table 4: Annual IV antibiotic days for the three groups of specialist CF centres ('upper quarter', 
'middle half', 'lower quarter') for 2013 and 2014 
 
 2013 2014 
Upper 
quarter 
(n = 981) 
Middle 
half 
(n = 1867) 
Lower 
quarter 
(n = 1244) 
Upper 
quarter 
(n = 871) 
Middle 
half 
(n = 2167) 
Lower 
quarter 
(n = 1411) 
 
Annual IV antibiotic 
days, 
median (IQR) 
 
 
 
14 (0 ± 34) 
 
 
 
14 (0 ± 40) 
 
 
 
10 (0 ± 29) 
 
 
 
13 (0 ± 31) 
 
 
 
14 (0 ± 38) 
 
 
 
12 (0 ± 28) 
 
Annual IV antibiotic 
days stratified 
according to FEV1, 
median (IQR) 
 
FEV1 < 40% 
FEV1 40% to 69.9% 
FEV1  
 
 
 
 
 
51 (28 ± 79) 
15 (0 ± 41) 
0 (0 ± 14) 
 
 
 
 
 
42 (14 ± 77) 
15 (0 ± 42) 
0 (0 ± 14) 
 
 
 
 
 
36 (14 ± 78) 
14 (0 ± 31) 
0 (0 ± 7) 
 
 
 
 
 
45 (20 ± 80) 
14 (0 ± 37) 
0 (0 ± 14) 
 
 
 
 
 
43 (17 ± 73) 
17 (0 ± 42) 
0 (0 ± 14) 
 
 
 
 
 
33 (14 ± 70) 
14 (0 ± 29) 
0 (0 ± 12) 
 
For 2013 
P-value for upper quarter vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for middle half vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for upper quarter vs middle half = 0.823 (after Bonferroni correction, p-value = 1) 
 
 
For 2014 
P-value for upper quarter vs lower quarter < 0.001 (after Bonferroni correction, p-value = 0.003) 
P-value for middle half vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for upper quarter vs middle half = 0.299 (after Bonferroni correction, p-value = 0.898) 
 
 
*P-values were calculated for annual IV antibiotic days stratified according to FEV1 using the 
stratified Wilcoxon rank sum test (van Elteren test). This test is an extension of the Wilcoxon rank 
sum test that uses within-stratum ranks to compare two groups that are stratified. For references, 
see: 
van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat 
Inst1960;37(3):351-361. 
Kawaguchi A, Koch GG. Sanon: an R package for stratified analysis with nonparametric covariable 
adjustment. J Stat Softw. 2015;67(9):1±37. 
 
Table 5: Percentage of adults prescribed at least one IV antibiotics course in a year for 2013 and 
2014 
 
 2013 2014 
Upper 
quarter 
(n = 981) 
Middle 
half 
(n = 1867) 
Lower 
quarter 
(n = 1244) 
Upper 
quarter 
(n = 871) 
Middle 
half 
(n = 2167) 
Lower 
quarter 
(n = 1411) 
 
People prescribed at 
least one course of 
IV antibiotics, (%) 
 
 
 
 
552 (56.3) 
 
 
 
 
1114 (59.7) 
 
 
 
 
648 (52.1) 
 
 
 
 
475 (54.5) 
 
 
 
 
1243 (57.4) 
 
 
 
 
780 (55.3) 
 
People prescribed at 
least one course of 
IV antibiotics 
stratified according 
to FEV1, (%) 
 
FEV1 < 40% 
FEV1 40% to 69.9% 
FEV1  
 
 
 
 
 
 
124 (91.9) 
252 (67.7) 
176 (37.1) 
 
 
 
 
 
 
287 (83.7) 
501 (69.9) 
326 (40.4) 
 
 
 
 
 
 
237 (80.6) 
285 (61.4) 
126 (25.9) 
 
 
 
 
 
 
112 (89.6) 
200 (66.9) 
163 (36.5) 
 
 
 
 
 
 
305 (85.0) 
565 (69.0) 
373 (37.7) 
 
 
 
 
 
 
266 (80.4) 
343 (63.6) 
171 (31.6) 
 
For 2013 
P-value for upper quarter vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for middle half vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for upper quarter vs middle half = 0.573 (after Bonferroni correction, p-value = 1) 
 
For 2014 
P-value for upper quarter vs lower quarter = 0.014 (after Bonferroni correction, p-value = 0.041) 
P-value for middle half vs lower quarter = 0.001 (after Bonferroni correction, p-value = 0.002) 
P-value for upper quarter vs middle half = 0.750 (after Bonferroni correction, p-value = 1) 
 
*P-values were calculated for the percentage of adults prescribed at least one IV antibiotics course 
in a year stratified according to FEV1 using the Cochran-Mantel-Haenszel test. This test is an 
extension of the chi-square test, and is used to determine the presence of consistent difference in 
proportions across stratified subgroups. For references, see: 
Cochran WG. 6RPH0HWKRGVIRU6WUHQJWKHQLQJWKH&RPPRQȤ7HVWV. Biometrics 1954;10(4):417-
351. 
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of 
disease. J Natl Cancer Inst 1959;22(4):719-748.  
Table 6: Prescription of preventive therapies for the three groups of specialist CF centres ('upper 
quarter', 'middle half', 'lower quarter') for 2013 and 2014 
 
 2013 2014 
Upper 
quarter 
(n = 983) 
Middle 
half 
(n = 1869) 
Lower 
quarter 
(n = 1244) 
Upper 
quarter 
(n = 871) 
Middle 
half 
(n = 2167) 
Lower 
quarter 
(n = 1411) 
 
People prescribed 
any form of 
preventive therapy, 
(%) 
 
 
 
 
 
873 (88.8) 
 
 
 
 
 
1621 (86.7) 
 
 
 
 
 
1079 (86.7) 
 
 
 
 
 
772 (88.6) 
 
 
 
 
 
1888 (87.1) 
 
 
 
 
 
1300 (92.1) 
 
People prescribed 
any form of 
preventive therapy 
stratified according 
to FEV1, (%) 
 
FEV1 < 40% 
FEV1 40% to 69.9% 
FEV1  
 
 
 
 
 
 
135 (100.0) 
354 (95.2) 
384 (80.7) 
 
 
 
 
 
 
335 (97.7) 
661 (92.2) 
625 (77.3) 
 
 
 
 
 
 
281 (95.6) 
435 (93.8) 
363 (74.7) 
 
 
 
 
 
 
124 (99.2) 
291 (97.3) 
357 (79.9) 
 
 
 
 
 
 
349 (97.2) 
774 (94.5) 
765 (77.4) 
 
 
 
 
 
 
330 (99.7) 
525 (97.4) 
445 (82.3) 
 
For 2013 
P-value for upper quarter vs lower quarter = 0.005 (after Bonferroni correction, p-value = 0.015) 
P-value for middle half vs lower quarter = 0.485 (after Bonferroni correction, p-value = 1) 
P-value for upper quarter vs middle half = 0.019 (after Bonferroni correction, p-value = 0.057) 
 
For 2014 
P-value for upper quarter vs lower quarter = 0.363 (after Bonferroni correction, p-value = 1) 
P-value for middle half vs lower quarter < 0.001 (after Bonferroni correction, p-value < 0.001) 
P-value for upper quarter vs middle half = 0.058 (after Bonferroni correction, p-value = 0.173) 
 
*P-values were calculated for the prescription of any pulmonary preventive therapies (inhaled 
antibiotics / inhaled mucolytics / long-term oral macrolide) stratified according to FEV1 using the 
Cochran-Mantel-Haenszel test. This test is an extension of the chi-square test, and is used to 
determine the presence of consistent difference in proportions across stratified subgroups. For 
references, see: 
Cochran WG. 6RPH0HWKRGVIRU6WUHQJWKHQLQJWKH&RPPRQȤ7HVWV. Biometrics 1954;10(4):417-
351. 
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of 
disease. J Natl Cancer Inst 1959;22(4):719-748. 
